Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel Tarning

Showing results (221-230 of 248) with videos related to

Pageof 25
Sort By:
Plos Medicine|January 11, 2017
Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-AnalysisRichard M Hoglund, Lesley Workman, Michael D Edstein, et al.
The Lancet. Infectious Diseases|December 3, 2022
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trialWalter R Taylor, Peter Olupot-Olupot, Marie A Onyamboko, et al.
The New England Journal of Medicine|October 8, 2020
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, Peter Horby, Marion Mafham, et al.
The Lancet. Infectious Diseases|June 10, 2021
Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trialMainga Hamaluba, Rob W van der Pluijm, Joseph Weya, et al.
British Journal of Clinical Pharmacology|October 6, 2025
Population pharmacokinetics of artemether-lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malariaJunjie Ding, Richard M Hoglund, Rob W van der Pluijm, et al.
Ebiomedicine|November 24, 2020
Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenzaYeming Wang, Wu Zhong, Alex Salam, et al.
The European Respiratory Journal|December 18, 2025
Efficacy of isoniazid in pediatric tuberculosis: an individual participant data meta-analysisAgathe Béranger, Belén P Solans, Ryo Miyakawa, et al.
Microorganisms|August 26, 2022
Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19Frauke Assmus, Jean-Sélim Driouich, Rana Abdelnabi, et al.
Malaria Journal|September 10, 2021
Development of weight and age-based dosing of daily primaquine for radical cure of vivax malariaWalter Robert Taylor, Richard M Hoglund, Pimnara Peerawaranun, et al.
Open Forum Infectious Diseases|August 2, 2021
High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH StudyBarnaby Flower, Leanne McCabe, Chau Le Ngoc, et al.
Pageof 25

Showing results (221-230 of 248) with videos related to

Sort By:
Pageof 25
Plos Medicine|January 11, 2017
Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-AnalysisRichard M Hoglund, Lesley Workman, Michael D Edstein, et al.
The Lancet. Infectious Diseases|December 3, 2022
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trialWalter R Taylor, Peter Olupot-Olupot, Marie A Onyamboko, et al.
The New England Journal of Medicine|October 8, 2020
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, Peter Horby, Marion Mafham, et al.
The Lancet. Infectious Diseases|June 10, 2021
Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trialMainga Hamaluba, Rob W van der Pluijm, Joseph Weya, et al.
British Journal of Clinical Pharmacology|October 6, 2025
Population pharmacokinetics of artemether-lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malariaJunjie Ding, Richard M Hoglund, Rob W van der Pluijm, et al.
Ebiomedicine|November 24, 2020
Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenzaYeming Wang, Wu Zhong, Alex Salam, et al.
The European Respiratory Journal|December 18, 2025
Efficacy of isoniazid in pediatric tuberculosis: an individual participant data meta-analysisAgathe Béranger, Belén P Solans, Ryo Miyakawa, et al.
Microorganisms|August 26, 2022
Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19Frauke Assmus, Jean-Sélim Driouich, Rana Abdelnabi, et al.
Malaria Journal|September 10, 2021
Development of weight and age-based dosing of daily primaquine for radical cure of vivax malariaWalter Robert Taylor, Richard M Hoglund, Pimnara Peerawaranun, et al.
Open Forum Infectious Diseases|August 2, 2021
High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH StudyBarnaby Flower, Leanne McCabe, Chau Le Ngoc, et al.
Pageof 25